Pharma Focus Europe


The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

Phenomic and Boehringer Ingelheim Establish Strategic Collaboration for the Discovery of Novel Targets in Stroma-Enriched Cancer Therapies

Thursday, November 30, 2023

Phenomic AI has recently announced a strategic collaboration and licensing agreement with Boehringer Ingelheim focusing on the identification of targets crucial in stromarich cancers The collaboration

OncoResponse Initiates Phase 1/2 Clinical Trial for OR502, an Anti-LILRB2 Antibody, in Patients with Advanced Cancer

Thursday, November 30, 2023

OncoResponse a clinicalstage biotech company specializing in immunotherapies derived from the immune systems of Elite Cancer Responders has recently initiated the Phase trial for OR

Ethris Secures Approval for Phase I Clinical Trial of ETH47, an Innovative Inhaled mRNA Solution for Respiratory Viral Infections

Wednesday, November 29, 2023

Ethris GmbH a leading biotechnology company focused on advancing nextgeneration RNA therapeutics and vaccines has secured approval from the United Kingdom Medicines and Healthcare products

Roslinct and Vertex Pharmaceuticals Inc to Collaborate on Manufacturing Exagamglogene Autotemcel (Exa-cel) Following Extensive Development Partnership

Wednesday, November 29, 2023

RoslinCT a Contract Development and Manufacturing Organization specializing in cell and gene therapy has announced its involvement in manufacturing the worlds first CRISPRbased therapy

TC BioPharm Receives FDA Clearance for Phase 1B Investigational New Drug (IND) TCB-008 in Acute Myeloid Leukemia

Tuesday, November 28, 2023

TC BioPharm PLC a biotechnology company focused on developing allogeneic gammadelta T cell therapies for cancer has received clearance from the FDA

FDA Grants Approval for Initial Treatment of Rare Non-Cancerous Tumors

Tuesday, November 28, 2023

Today the US Food and Drug Administration has granted approval for Ogsiveo nirogacestat tablets marking a significant milestone as the first drug sanctioned for the treatment

FDA Grants Orphan Drug Designation to Mocravimod for Allogeneic HSCT in Hematologic Malignancies - Priothera

Monday, November 27, 2023

Priothera Ltd has announced that the US Food and Drug Administration granted Orphan Drug designation to its compound mocravimod a SP receptor modulator This designation is for the treatment aimed

Medivir Introduces an Improved Formulation of Fostrox, Essential for Facilitating a Planned Study Aimed at Accelerated Approval in the Second-line Treatment of Hepatocellular Carcinoma

Monday, November 27, 2023

Medivir AB recently reported the successful completion of the development of an updated formulation of fostrox intended for commercial manufacturing Fostrox created by the pharmaceutical company

Er-kim Pharmaceuticals Actively Supports the Global Campaign to Prevent Antimicrobial Resistance (Amr)

Friday, November 24, 2023

ErKim Pharmaceuticals an international pharmaceutical company specializing in the commercialization of novel therapies has joined the effort to combat antimicrobial resistance by participating in World AMR

Boehringer Ingelheim Expands Its Immuno-oncology Portfolio Through the Acquisition of T3 Pharma, a Specialist in Bacterial Cancer Therapy

Thursday, November 23, 2023

Boehringer Ingelheim has recently completed the acquisition of T Pharmaceuticals AG a Swiss biotech company for an amount of up to million CHF T Pharma specializes in a unique therapy platform

Get instant
access to our latest e-book